Patients enrolled in Part 2 must have histologically documented locally advanced or metastatic colorectal cancer that has relapsed after or is refractory to oxaliplatin and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.
I - Research Studies that focus on the safety of a drug. The goal is to determine the drug's most frequent and serious adverse events and, often, how the drug is broken down and excreted by the body. These studies usually involve a small number of participants.
Highlands Ranch Hospital
University of Colorado Hospital
Antonio Jimeno, MD
Protocol Number: 18-1721
More information available at ClinicalTrials.gov: NCT03616574
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers